Valuation: OpGen Inc

Market Cap 204M 179M 164M 153M 290M 19.46B 295M 1.97B 766M 9.56B 767M 751M 32.96B P/E 2024
0.26x
P/E 2025 6.86x
Enterprise Value 206M 180M 165M 154M 292M 19.58B 297M 1.98B 771M 9.63B 772M 755M 33.17B EV / Sales 2024
1.29x
EV / Sales 2025 5.39x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 50 2025-11-30
Chief Tech/Sci/R&D Officer 37 2025-03-31
Chief Operating Officer 54 2024-12-03
Director TitleAgeSince
Chairman 36 2024-08-01
Director/Board Member 39 2024-08-08
Director/Board Member 40 2024-08-08
Change 5-day change 1-year change 3-year change Capi.($)
+21.45%+1,817.73% - - 6.39M
+1.70%+7.41%+2.50%+8.18% 49.92B
+0.92%+3.93%+399.71%+604.02% 40.23B
+1.89%+8.32%+26.06%-6.27% 34.55B
+2.38%+6.35%+21.25%+55.45% 33.09B
+3.96%+10.67%+8.30%+37.95% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+135.37% 15.92B
+0.32%+0.58%+14.00%+19.09% 13.86B
+3.30%+0.76%+90.23%+93.88% 13.52B
Average +4.10%+5.82%+79.44%+118.46% 27.3B
Weighted average by Cap. +2.07%+6.53%+90.20%+135.87%

Financials

2024 2025
Net sales 5.2M 4.54M 4.17M 3.89M 7.38M 495M 7.49M 50.12M 19.48M 243M 19.5M 19.09M 838M 30.2M 26.4M 24.26M 22.62M 42.89M 2.88B 43.55M 291M 113M 1.41B 113M 111M 4.87B
Net income 11.99M 10.48M 9.63M 8.98M 17.03M 1.14B 17.29M 116M 44.97M 561M 45.02M 44.05M 1.93B 23.62M 20.65M 18.98M 17.69M 33.55M 2.25B 34.06M 228M 88.56M 1.11B 88.66M 86.76M 3.81B
Net Debt 711K 622K 571K 532K 1.01M 67.69M 1.03M 6.86M 2.67M 33.28M 2.67M 2.61M 115M 1.32M 1.15M 1.06M 986K 1.87M 125M 1.9M 12.7M 4.94M 61.62M 4.94M 4.84M 212M
Logo OpGen Inc
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Employees
-